RecruitingPhase 2NCT04143724
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Studying Beta-thalassemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- ACE-536(drug)
- Enrollment
- 99 enrolled
- Eligibility
- 6-17 years · All sexes
- Timeline
- 2019 – 2035
Study locations (26)
- Local Institution - 601, Los Angeles, California, United States
- New York Presbyterian Hospital, New York, New York, United States
- Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
- Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
- People's Liberation Army The 923rd Hospital, Nanning, GX, China
- West China Hospital - Sichuan University, Chengdu, Sichuan, China
- Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
- The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Universitätsklinikum Essen, Essen, Germany
- Universitatsklinikum Ulm, Ulm, Germany
- General Children's Hospital "Agia Sophia", Athens, Greece
- Kamala Hospital and Research Center, Hyderabad, Andhra Pradesh, India
- MCGM - Comprehensive Thalassemia Care, Pediatric Hematology-Oncology & BMT Centre, Borivali (E), Mumbai, Maharashtra, India
- Kingsway Hospitals, Nagpur, Maharashtra, India
- Post Graduate Institute of Child Health, Noida, Uttar Pradesh, India
- +11 more locations on ClinicalTrials.gov
Collaborators
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04143724 on ClinicalTrials.govOther trials for Beta-thalassemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07215975A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle EastBristol-Myers Squibb
- ENROLLING BY INVITATIONNCT07055503Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia PatientsUniversity Research Institute for the Study of Genetic & Malignant Disorders in Childhood
- RECRUITINGNANCT07207577Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTDCentre Hospitalier Metropole Savoie
- ENROLLING BY INVITATIONNCT06717932A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 InjectionCorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT06364774ALS20-101 Lentiviral Gene Therapy for Beta ThalassemiaChildren's Hospital of Philadelphia
- ENROLLING BY INVITATIONNCT06685536A Long-term Follow-up Study in Participants Who Received CS-101CorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1NCT06772766A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaMabwell (Shanghai) Bioscience Co., Ltd.
- RECRUITINGNANCT06734520Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemiaGuangzhou Women and Children's Medical Center